GlassScriptPhysician profile
Daniel Nguyen
NPI 1467794560
$47,296.41
in general payments reported to CMS, 2019-2025
27 companies · $6,157 in 2025
The $6,157 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $16K · 2021: $3,936 · 2022: $2,244 · 2023: $1,459 · 2024: $1,535 · 2025: $6,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,132 · Consulting Fee: $1,875 · Travel and Lodging: $1,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,132.04 |
| Consulting Fee | $1,875.00 |
| Travel and Lodging | $1,143.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $16,811.88 | 2019-2020 | |
| Boston Scientific Corporation | $13,608.51 | 2019-2025 | Farapulse, General - Therapies, Watchman Access System |
| Abbott Laboratories | $7,858.74 | 2019-2025 | Aveir, Confirm Rx, Tendril |
| Altathera Pharmaceuticals LLC | $2,253.26 | 2025 | Sotalol Hydrochloride |
| Biotronik INC. | $2,073.68 | 2020-2025 | Amvia Edge, Pamira, Acticor 7 Vr-T Dx |
| Medtronic, INC. | $1,867.42 | 2021-2025 | Azure Xt Dr Mri Surescan, Aurora Ev-Icd Mri Surescan, Micra |
| Biosense Webster, INC. | $917.89 | 2019-2025 | Carto 3, Qdot Micro Catheter, Nuvision Ice Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $342.09 | 2019-2025 | Lifevest |
| Atricure, INC. | $251.70 | 2019-2023 | |
| Cardiva Medical, INC. | $184.58 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f, Cardiva Vascade 6/7f Vcs |
| Cordis US Corp. | $162.61 | 2025 | Mynx Control Venous |
| Novartis Pharmaceuticals Corporation | $135.30 | 2019-2023 | |
| Alnylam Pharmaceuticals INC. | $123.03 | 2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $117.21 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $100.62 | 2023-2024 | Assure Wcd |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $75.13 | 2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $72.68 | 2020-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $55.91 | 2023 | |
| Philips North America LLC | $48.28 | 2020 | |
| Pfizer INC. | $46.37 | 2021-2024 | |
| Irhythm Technologies, INC. | $43.68 | 2023 | Zio Xt Patch |
| Elutia, INC. | $39.79 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.10 | 2023 | |
| Cook Medical LLC | $25.16 | 2024 | Zenith Alpha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.85 | 2023 | Jardiance |
| Impulse Dynamics (USA) INC. | $16.36 | 2023 | Optimizer |
| Medicomp INC | $15.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.